KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Design of Antigen-Specific Immunotherapies Through Modulation of Peripheral Tolerance Pathways

    Thumbnail
    View/Open
    Available after: 2020-08-31 (3.105Mb)
    Issue Date
    2019-08-31
    Author
    Christopher, Matthew Alexander
    Publisher
    University of Kansas
    Format
    116 pages
    Type
    Dissertation
    Degree Level
    Ph.D.
    Discipline
    Pharmaceutical Chemistry
    Rights
    Copyright held by the author.
    Metadata
    Show full item record
    Abstract
    Current therapies for autoimmune diseases lack specificity for the offending immune cell population resulting in a wide range of side effects and weakening of the immune system. This presents a clear need for antigen-specific immunotherapies (ASITs) capable of selectively modulating autoreactive immune cells while maintaining the patient’s ability to respond to foreign pathogens. Lymphocyte activation is dependent on receiving two signals in tandem: interaction with the antigen of interest and co-stimulatory signals. Disruption of this two-signal model for lymphocyte activation in the context of the autoantigen is key to developing successful ASITs. Antigen-drug conjugates represent a novel class of therapeutics for the induction of immune tolerance designed to direct the effects of small molecule immunosuppressants through conjugation to the autoantigen of interest (Chapter 2). This strategy has proven successful in ameliorating paralytic symptoms in a murine model of multiple sclerosis (MS) known as experimental autoimmune encephalomyelitis (EAE). This was achieved through conjugation of the corticosteroid dexamethasone (DEX) to the peptide autoantigen proteolipid protein (PLP139-151). Further studies into the disruption of co-stimulatory signals in EAE revealed a protective role for the programmed cell death 1 (PD-1) pathway, and antagonism of natural receptor engagement resulted in cellular exhaustion, alleviating inflammatory markers (Chapter 3). Ultimately, antigen-only ASITs represent possibly the safest form of immune modulation in autoimmune diseases and may be achieved through multivalent displays of autoantigen. For example, a tetravalent display of PLP139-151 (4-arm PLP139-151) completely ameliorated EAE symptoms through depletion of PLP-responsive B cells and induction of a tolerogenic shift in co-stimulatory markers (Chapter 4). These results support the advancement of multiple avenues of approach in the development of ASIT for treating autoimmunity.
    URI
    http://hdl.handle.net/1808/29841
    Collections
    • Dissertations [4475]
    • Pharmaceutical Chemistry Dissertations and Theses [141]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps